Monitoring and Managing Patients with Tuberous Sclerosis Complex: Current State of Knowledge

References

• Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008;372(9639):657–668. doi:10.1016/S0140-6736(08)61279-9
   PubMed Web of Science ®Google Scholar
• Northrup H, Krueger DA, International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49(4):243–254. doi:10.1016/j.pediatrneurol.2013.08.001
   PubMed Web of Science ®Google Scholar
• O’Callaghan FJ, Shiell AW, Osborne JP, Martyn CN. Prevalence of tuberous sclerosis estimated by capture-recapture analysis. Lancet. 1998;351(9114):1490. doi:10.1016/S0140-6736(05)78872-3
   PubMed Web of Science ®Google Scholar
• Lendvay TS, Marshall FF. The tuberous sclerosis complex and its highly variable manifestations. J Urol. 2003;169(5):1635–1642. doi:10.1097/01.ju.0000058253.40352.60
   PubMed Web of Science ®Google Scholar
• Palavra F, Robalo C, Reis F. Recent advances and challenges of mTOR inhibitors use in the treatment of patients with tuberous sclerosis complex. Oxid Med Cell Longev. 2017;2017:9820181. doi:10.1155/2017/9820181
   PubMed Web of Science ®Google Scholar
• Portocarrero LKL, Quental KN, Samorano LP, Oliveira ZNP, Rivitti-Machado MCM. Tuberous sclerosis complex: review based on new diagnostic criteria. An Bras Dermatol. 2018;93(3):323–331. doi:10.1590/abd1806-4841.20186972
   PubMed Web of Science ®Google Scholar
• Jesus-Ribeiro J, Palavra F, Reis F. Chapter 99: Tuberous Sclerosis Complex, Handbook of Tumor Syndromes. 1st ed. Boca Raton: CRC Press; 2020. DOI:10.1201/9781351187435
   Google Scholar
• European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993;75(7):1305–1315. doi:10.1016/0092-8674(93)90618-Z
   PubMed Web of Science ®Google Scholar
• van Slegtenhorst M, de Hoogt R, Hermans C, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997;277(5327):805. doi:10.1126/science.277.5327.805
   PubMed Web of Science ®Google Scholar
• Langkau N, Martin N, Brandt R, et al. TSC1 and TSC2 mutations in tuberous sclerosis, the associated phenotypes and a model to explain observed TSC1/ TSC2 frequency ratios. Eur J Pediatr. 2002;161(7):393–402. doi:10.1007/s00431-001-0903-7
   PubMed Web of Science ®Google Scholar
• Huang J, Dibble CC, Matsuzaki M, Manning BD. The TSC1- TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol. 2008;28(12):4104–4115. doi:10.1128/MCB.00289-08
   PubMed Web of Science ®Google Scholar
• Garami A, Zwartkruis FJ, Nobukuni T, et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell. 2003;11(6):1457–1466. doi:10.1016/S1097-2765(03)00220-X
   PubMed Web of Science ®Google Scholar
• Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell. 2002;10(1):151–162. doi:10.1016/S1097-2765(02)00568-3
   PubMed Web of Science ®Google Scholar
• Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci USA. 2004;101(37):13489–13494. doi:10.1073/pnas.0405659101
   PubMed Web of Science ®Google Scholar
• Jozwiak J, Jozwiak S, Grzela T, Lazarczyk M. Positive and negative regulation of TSC2 activity and its effects on downstream effectors of the mTOR pathway. Neuromolecular Med. 2005;7(4):287–296. doi:10.1385/NMM:7:4:287
   PubMed Web of Science ®Google Scholar
• Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol. 2003;5(6):578–581. doi:10.1038/ncb999
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274–293. doi:10.1016/j.cell.2012.03.017
   PubMed Web of Science ®Google Scholar
• Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol. 2004;6(11):1122–1128. doi:10.1038/ncb1183
   PubMed Web of Science ®Google Scholar
• Jones AC, Shyamsundar MM, Thomas MW, et al. Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Am J Hum Genet. 1999;64(5):1305–1315. doi:10.1086/302381
   PubMed Web of Science ®Google Scholar
• van Slegtenhorst M, Verhoef S, Tempelaars A, et al. Mutational spectrum of the TSC1 gene in a cohort of 225 tuberous sclerosis complex patients: no evidence for genotype-phenotype correlation. J Med Genet. 1999;36(4):285–289.
   PubMed Web of Science ®Google Scholar
• Kozlowski P, Roberts P, Dabora S, et al. Identification of 54 large deletions/duplications in TSC1 and TSC2 using MLPA, and genotype-phenotype correlations. Hum Genet. 2007;121(3–4):389–400. doi:10.1007/s00439-006-0308-9
   PubMed Web of Science ®Google Scholar
• Dabora SL, Franz DN, Ashwal S, et al. Multicenter Phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF-D levels decrease. PLoS One. 2011;6(9):e23379. doi:10.1371/journal.pone.0023379
   PubMed Web of Science ®Google Scholar
• Davies DM, de Vries PJ, Johnson SR, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res. 2011;17(12):4071–4081. doi:10.1158/1078-0432.CCR-11-0445
   PubMed Web of Science ®Google Scholar
• McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. New Engl J Med. 2011;364(17):1595–1606. doi:10.1056/NEJMoa1100391
   PubMed Web of Science ®Google Scholar
• Sancak O, Nellist M, Goedbloed M, et al. Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype–phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex. Eur J Hum Genet. 2005;13(6):731–741. doi:10.1038/sj.ejhg.5201402
   PubMed Web of Science ®Google Scholar
• Dabora SL, Jozwiak S, Franz DN, et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet. 2001;68(1):64–80. doi:10.1086/316951
   PubMed Web of Science ®Google Scholar
• Frassanito P, Noya C, Tamburrino G. Current trends in the management of subependymal giant cell astrocytomas in tuberous sclerosis. Childs Nerv Syst. 2020;36(10):2527–2536. doi:10.1007/s00381-020-04889-9
   PubMed Web of Science ®Google Scholar
• Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355(13):1345–1356. doi:10.1056/NEJMra055323
   PubMed Web of Science ®Google Scholar
• Franz DN, Belousova E, Sparagana S, et al. Long-term use of everolimus in patients with tuberous sclerosis complex: final results from the EXIST-1 study. PLoS One. 2016;11(6):e0158476. doi:10.1371/journal.pone.0158476
   PubMed Web of Science ®Google Scholar
• Sasongko TH, Ismail NF, Zabidi-Hussin Z. Rapamycin and rapalogs for tuberous sclerosis complex. Cochrane Database Syst Rev. 2016;7(7):Cd011272. doi:10.1002/14651858.CD011272.pub2
   PubMed Web of Science ®Google Scholar
• Curatolo P, Bjornvold M, Dill PE, et al. The role of mTOR inhibitors in the treatment of patients with tuberous sclerosis complex: evidence-based and expert opinions. Drugs. 2016;76(5):551–565. doi:10.1007/s40265-016-0552-9
   PubMed Web of Science ®Google Scholar
• MacKeigan JP, Krueger DA. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex. Neuro Oncol. 2015;17(12):1550–1559. doi:10.1093/neuonc/nov152
   PubMed Web of Science ®Google Scholar
• Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013;381(9861):125–132. doi:10.1016/S0140-6736(12)61134-9
   PubMed Web of Science ®Google Scholar
• Franz DN, Capal JK. mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders. Orphanet J Rare Dis. 2017;12(1):51. doi:10.1186/s13023-017-0596-2
   PubMed Web of Science ®Google Scholar
• Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9869):817–824. doi:10.1016/S0140-6736(12)61767-X
   PubMed Web of Science ®Google Scholar
• Gupta N, Henske EP. Pulmonary manifestations in tuberous sclerosis complex. Am J Med Genet C Semin Med Genet. 2018;178(3):326–337. doi:10.1002/ajmg.c.31638
   PubMed Web of Science ®Google Scholar
• Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008;358(2):140–151. doi:10.1056/NEJMoa063564
   PubMed Web of Science ®Google Scholar
• Sadowski K, Kotulska K, Jozwiak S. Management of side effects of mTOR inhibitors in tuberous sclerosis patients. Pharmacol Rep. 2016;68(3):536–542. doi:10.1016/j.pharep.2016.01.005
   PubMed Web of Science ®Google Scholar
• Wataya-Kaneda M, Uemura M, Fujita K, et al. Tuberous sclerosis complex: recent advances in manifestations and therapy. Int J Urol. 2017;24(9):681–691. doi:10.1111/iju.13390
   PubMed Web of Science ®Google Scholar
• Ebrahimi-Fakhari D, Meyer S, Vogt T, Pfohler C, Muller CSL. Dermatological manifestations of tuberous sclerosis complex (TSC). J Dtsch Dermatol Ges. 2017;15(7):695–700.
   Web of Science ®Google Scholar
• Wheless JW, Almoazen H. A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex. J Child Neurol. 2013;28(7):933–936. doi:10.1177/0883073813488664
   PubMed Web of Science ®Google Scholar
• Lin YT, Yu CL, Tu YK, Chi CC. Efficacy and safety of topical mechanistic target of rapamycin inhibitors for facial angiofibromas in patients with tuberous sclerosis complex: a systematic review and network meta-analysis. Biomedicines. 2022;10(4):826. doi:10.3390/biomedicines10040826
   PubMed Web of Science ®Google Scholar
• Rowley SA, O’Callaghan FJ, Osborne JP. Ophthalmic manifestations of tuberous sclerosis: a population based study. Brit J Ophthalmol. 2001;85(4):420–423. doi:10.1136/bjo.85.4.420
   PubMed Web of Science ®Google Scholar
• Kwiatkowska J, Waldoch A, Meyer-Szary J, Potaz P, Grzybiak M. Cardiac tumors in children: a 20-year review of clinical presentation, diagnostics and treatment. Adv Clin Exp Med. 2017;26(2):319–326. doi:10.17219/acem/62121
   PubMed Web of Science ®Google Scholar
• Dahdah N. Everolimus for the treatment of tuberous sclerosis complex–related cardiac rhabdomyomas in pediatric patients. J Pediatr. 2017;190:21–26.e7. doi:10.1016/j.jpeds.2017.06.076
   PubMed Web of Science ®Google Scholar
• Sugalska M, Tomik A, Józwiak S, Werner B. Treatment of cardiac rhabdomyomas with mTOR inhibitors in children with tuberous sclerosis complex – a systematic review. Int J Environ Res Public Health. 2021;18(9):4907. doi:10.3390/ijerph18094907
   PubMed Web of Science ®Google Scholar
• Stelmaszewski EV, Parente DB, Farina A, et al. Everolimus for cardiac rhabdomyomas in children with tuberous sclerosis. The ORACLE study protocol (everOlimus for caRdiac rhAbdomyomas in tuberous sCLErosis): a randomised, multicentre, placebo-controlled, double-blind Phase II trial. Cardiol Young. 2020;30(3):337–345. doi:10.1017/S1047951119003147
   PubMed Web of Science ®Google Scholar
• Nabbout R, Belousova E, Benedik MP, et al. Historical patterns of diagnosis, treatments, and outcome of epilepsy associated with tuberous sclerosis complex: results from TOSCA registry. Front Neurol. 2021;12:697467. doi:10.3389/fneur.2021.697467
   PubMed Web of Science ®Google Scholar
• Calcagnotto ME, Paredes MF, Tihan T, Barbaro NM, Baraban SC. Dysfunction of synaptic inhibition in epilepsy associated with focal cortical dysplasia. J Neurosci. 2005;25(42):9649–9657. doi:10.1523/JNEUROSCI.2687-05.2005
   PubMed Web of Science ®Google Scholar
• Guerrini R, Carrozzo R. Epileptogenic brain malformations: clinical presentation, malformative patterns and indications for genetic testing. Seizure. 2001;10(7):532–543. doi:10.1053/seiz.2001.0650
   PubMed Web of Science ®Google Scholar
• Leo A, Constanti A, Coppola A, Citraro R, De Sarro G, Russo E. Chapter 8 – mTOR signaling in epilepsy and epileptogenesis: preclinical and clinical studies. Maiese, Kenneth. In: Molecules to Medicine with mTOR. Boston: Academic Press; 2016:123–142.
   Google Scholar
• Orlova KA, Crino PB. The tuberous sclerosis complex. Ann New York Acad Sci. 2010;1184:87–105. doi:10.1111/j.1749-6632.2009.05117.x
   PubMed Web of Science ®Google Scholar
• Chu-Shore CJ, Major P, Camposano S, Muzykewicz D, Thiele EA. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia. 2010;51(7):1236–1241. doi:10.1111/j.1528-1167.2009.02474.x
   PubMed Web of Science ®Google Scholar
• DiMario FJ. Brain abnormalities in tuberous sclerosis complex. J Child Neurol. 2004;19(9):650–657. doi:10.1177/08830738040190090401
   PubMed Web of Science ®Google Scholar
• Chan JA, Zhang H, Roberts PS, et al. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J Neuropathol Exp Neurol. 2004;63(12):1236–1242. doi:10.1093/jnen/63.12.1236
   PubMed Web of Science ®Google Scholar
• Baybis M, Yu J, Lee A, et al. mTOR cascade activation distinguishes tubers from focal cortical dysplasia. Ann Neurol. 2004;56(4):478–487. doi:10.1002/ana.20211
   PubMed Web of Science ®Google Scholar
• Crino PB, Henske EP. New developments in the neuro-biology of the tuberous sclerosis complex. Neurology. 1999;53(7):1384–1390. doi:10.1212/WNL.53.7.1384
   PubMed Web of Science ®Google Scholar
• Joinson C, O’Callaghan FJ, Osborne JP, Martyn C, Harris T, Bolton PF. Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex. Psychol Med. 2003;33(2):335–344. doi:10.1017/S0033291702007092
   PubMed Web of Science ®Google Scholar
• Kalantari BN, Salamon N. Neuroimaging of tuberous sclerosis: spectrum of pathologic findings and frontiers in imaging. Am J Roentgenol. 2008;190(5):W304–9. doi:10.2214/AJR.07.2928
   PubMed Web of Science ®Google Scholar
• Kotulska K, Borkowska J, Roszkowski M, et al. Surgical treatment of subependymal giant cell astrocytoma in tuberous sclerosis complex patients. Pediatr Neurol. 2014;50(4):307–312. doi:10.1016/j.pediatrneurol.2013.12.004
   PubMed Web of Science ®Google Scholar
• Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363(19):1801–1811. doi:10.1056/NEJMoa1001671
   PubMed Web of Science ®Google Scholar
• Kotulska K, Chmielewski D, Borkowska J, et al. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Eur J Paediatr Neurol. 2013;17(5):479–485. doi:10.1016/j.ejpn.2013.03.002
   PubMed Web of Science ®Google Scholar
• Moavero R, Cerminara C, Curatolo P. Epilepsy secondary to tuberous sclerosis: lessons learned and current challenges. Childs Nerv Syst. 2010;26(11):1495–1504. doi:10.1007/s00381-010-1128-8
   PubMed Web of Science ®Google Scholar
• Specchio N, Pavia GC, de Palma L, et al. Current role of surgery for tuberous sclerosis complex-associated epilepsy. Pediatr Investig. 2022;6(1):16–22. doi:10.1002/ped4.12312
   PubMedGoogle Scholar
• Krueger DA, Wilfong AA, Holland-Bouley K, et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol. 2013;74(5):679–687. doi:10.1002/ana.23960
   PubMed Web of Science ®Google Scholar
• French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388(10056):2153–2163. doi:10.1016/S0140-6736(16)31419-2
   PubMed Web of Science ®Google Scholar
• Canpolat M, Per H, Gumus H, et al. Rapamycin has a beneficial effect on controlling epilepsy in children with tuberous sclerosis complex: results of 7 children from a cohort of 86. Childs Nerv Syst. 2014;30(2):227–240. doi:10.1007/s00381-013-2185-6
   PubMed Web of Science ®Google Scholar
• Cardamone M, Flanagan D, Mowat D, Kennedy SE, Chopra M, Lawson JA. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex. J Pediatr. 2014;164(5):1195–1200. doi:10.1016/j.jpeds.2013.12.053
   PubMed Web of Science ®Google Scholar
• Wesseling H, Elgersma Y, Bahn S. A brain proteomic investigation of rapamycin effects in the Tsc1± mouse model. Mol Autism. 2017;8:41. doi:10.1186/s13229-017-0151-y
   PubMed Web of Science ®Google Scholar
• Hwang SK, Lee JH, Yang JE, et al. Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation. Mol Brain. 2016;9(1):56. doi:10.1186/s13041-016-0222-6
   PubMed Web of Science ®Google Scholar
• Schneider M, de Vries PJ, Schonig K, Rossner V, Waltereit R. mTOR inhibitor reverses autistic-like social deficit behaviours in adult rats with both Tsc2 haploinsufficiency and develop- mental status epilepticus. Eur Arch Psychiat Clin Neurosci. 2017;267(5):455–463. doi:10.1007/s00406-016-0703-8
   PubMed Web of Science ®Google Scholar
• Rosner M, Hengstschlager M. Tuberin binds p27 and negatively regulates its interaction with the SCF component Skp2. J Biol Chem. 2004;279(47):48707–48715. doi:10.1074/jbc.M405528200
   PubMed Web of Science ®Google Scholar
• Young LR, Vandyke R, Gulleman PM, et al. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest. 2010;138(3):674–681. doi:10.1378/chest.10-0573
   PubMed Web of Science ®Google Scholar
• Karbowniczek M, Astrinidis A, Balsara BR, et al. Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med. 2003;167(7):976–982. doi:10.1164/rccm.200208-969OC
   PubMed Web of Science ®Google Scholar
• Hatano T, Egawa S. Renal angiomyolipoma with tuberous sclerosis complex: how it differs from sporadic angiomyolipoma in both management and care. Asian J Surg. 2020;43(10):967–972. doi:10.1016/j.asjsur.2019.12.008
   PubMed Web of Science ®Google Scholar
• Halpenny D, Snow A, McNeill G, Torreggiani WC. The radiological diagnosis and treatment of renal angiomyolipoma-current status. Clin Radiol. 2010;65(2):99–108. doi:10.1016/j.crad.2009.09.014
   PubMed Web of Science ®Google Scholar
• Volpi A, Sala G, Lesma E, et al. Tuberous sclerosis complex: new insights into clinical and therapeutic approach. J Nephrol. 2019;32(3):355–363. doi:10.1007/s40620-018-0547-6
   PubMed Web of Science ®Google Scholar
• Feldman ME, Shokat KM. New inhibitors of the PI3KAkt-mTOR pathway: insights into mTOR signaling from a new generation of tor kinase domain inhibitors (TORKinibs). Curr Top Microbiol Immunol. 2010;347(1):241–262. doi:10.1007/82_2010_64
   PubMed Web of Science ®Google Scholar
• Sun SY. mTOR kinase inhibitors as potential cancer therapeutic drugs. Cancer Lett. 2013;340(1):1–8. doi:10.1016/j.canlet.2013.06.017
   PubMed Web of Science ®Google Scholar
• Karalis V, Bateup HS. Current approaches and future directions for the treatment of mTORopathies. Dev Neurosci. 2021;43(3–4):143–158. doi:10.1159/000515672
   PubMed Web of Science ®Google Scholar
• Liu HJ, Krymskaya VP, Henske EP. Immunotherapy for lymphangioleiomyomatosis and tuberous sclerosis: progress and future directions. Chest. 2019;156(6):1062–1067. doi:10.1016/j.chest.2019.08.005
   PubMed Web of Science ®Google Scholar
• Crino PB. The mTOR signalling cascade: paving new roads to cure neurological disease. Nat Rev Neurol. 2016;12(7):379–392. doi:10.1038/nrneurol.2016.81
   PubMed Web of Science ®Google Scholar
• Annear NMP, Appleton RE, Bassi Z, et al. Tuberous Sclerosis Complex (TSC): expert recommendations for provision of coordinated care. Front Neurol. 2019;10:1116. doi:10.3389/fneur.2019.01116
   PubMed Web of Science ®Google Scholar
• Auvin S, Bissler JJ, Cottin V, et al. A step-wise approach for establishing a multidisciplinary team for the management of tuberous sclerosis complex: a Delphi consensus report. Orphanet J Rare Dis. 2019;14(1):91. doi:10.1186/s13023-019-1072-y
   PubMed Web of Science ®Google Scholar
• Kingswood JC, Bruzzi P, Curatolo P, et al. TOSCA – first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complex. Orphanet J Rare Dis. 2014;9:182. doi:10.1186/s13023-014-0182-9
   PubMed Web of Science ®Google Scholar